16.49
+0.24%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai ZJ Bio-Tech Co
Its shares trade on Shanghai under the ticker 688317.SS. It has been listed since 18 January 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥124.9m and a net loss of CN¥34.3m. At that date it held total assets of CN¥3.76bn and shareholders' equity of CN¥3.35bn.
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents, and instruments and equipment. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-01-18. The firm is mainly engaged in the research, development, production and sales of genetic diagnostic reagents and equipment. The firm's main products include nucleic acid detection kits and molecular diagnostic instruments. The firm's products are mainly used in areas such as emergency public health safety, medical clinical diagnosis, entry-exit inspection and quarantine, and food safety. The firm mainly conducts business within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 18 Jan 2021
- Employees
- 435
- Website
- liferiver.com.cn ↗
Leadership
Pay as last reported
- Mr. Junbin ShaoChairman of the Board, since 2021CN¥1.2m
- Ms. Weiqin NiChief Financial Officer, Deputy General Manager, Secretary of the Board, Director, since 2021CN¥1.3m
- Ms. Liliang LuGeneral ManagerCN¥4.0m
- Mr. Jingming MaDeputy General Manager, Director, since 2022CN¥216,200
- Mr. Kai WangDeputy General ManagerCN¥4.0m
- Mr. Jie ZhangDeputy Director of R&D CenterCN¥437,700
- Mr. Xuerao LiIndependent DirectorCN¥95,200
- Mr. Yongsheng YuIndependent DirectorCN¥95,200
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai ZJ Bio-Tech Co Ltd employs 435 full-time staff members.
- The company went public on 18 January 2021 via an IPO.
- Products include nucleic acid detection kits and molecular diagnostic instruments.
Weaknesses
- The firm mainly conducts business within the domestic market only.
- Operations are headquartered in Shanghai, Shanghai, limiting geographic diversity.
- Employee count is 435, which may restrict large-scale production.
Opportunities
- Genetic diagnostic reagents serve emergency public health safety needs.
- Molecular diagnostic instruments support medical clinical diagnosis procedures effectively.
- Entry-exit inspection and quarantine sectors require reliable testing equipment.
Threats
- Food safety regulations demand strict compliance for diagnostic products.
- Domestic market focus limits international revenue growth potential significantly.
- Public health safety emergencies may fluctuate demand unpredictably over time.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.